Non-invasive method
UroBEST
_
can be performed with a spontaneous urine sample from the patient, taken at any time of the day
Easy-to-perfom Technology
UroBEST
_
is based on RT-qPCR, a widely spread technology present in most hospitals and laboratories
Quantitative diagnosis
UroBEST
_
quantifies the probability of
suffering BC based on
genetic expression levels
–
Validated results
UROBEST
has been validated in two prospective trials, both in European and Chinese populations, with excellent results
Bladder cancer is the second most frequent malignancy of the genito-urinary tract after prostate cancer
Bladder cancer high prevalence, survival and recurrence rates combine to make it one of the most expensive cancers to treat and monitor. The gold standard diagnostic tool is combined cystoscopy and cytology which is costly and highly invasive requiring transurethral access and presenting the risk of important complications and discomfort to patients. Because clinical symptoms are not useful in predicting progression, surveillance requires frequent cystoscopies, on average in excess of 13 per patient following initial diagnosis and treatment. Fina Biotech offers a solution for the diagnosis of bladder cancer which is:
- Non-invasive
- Robust and trustworthy
- Reproducible
- Non-observer dependent
- No time consuming
Validated in a two prospective multinational trials in Europe and China
6
5
914
80%
94%
HOSPITALS
COUNTRIES
PATIENTS
SENSITIVITY
SPECIFICITY
Contact usFina Biotech, Better Diagnosis for a Better Life
Contact us
Fina Biotech, Better Diagnosis for a Better Life
For any enquiry about our products, please phone us on +34 917 991 564
